Qiagen CEO Details Companion Dx Strategy and Near-Term Launches at UBS Life Sciences Meeting

"The drugs that are being associated with our diagnostic tests have market potential in existing sales in the multi-billions of dollars," Schatz said this week at an investor conference in New York.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.